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Aims: Many in-vitro systems used during pre-clinical trials fail to recreate the biological complexity of 
the in-vivo neural microenvironment. Taking advantage of recent advances in microfluidic 
technology, we seek to develop a perfusion based drug discovery platform that is capable of high-
throughput pharmacological profiling. This in turn will allow us to better understand how drugs 
influence the communication between functionally connected neural networks. 
Methods: Mixed primary hippocampal networks were grown in microfluidic devices with 
environmentally separated chambers that allow synaptic connections to be formed with each other 
via an array of microchannels. The perfusion of multiple compounds in one chamber was achieved 
using computer controlled fluid actuation connected to the inlets/outlets of the microfluidic device. 
Responses to perfusates from directly stimulated neurons and those synaptically connected were 
recorded using calcium imaging. 
Results: Following live/dead assays, the flow rate that showed the greatest cell viability was used for 
subsequent experiments. Subsequently, a glutamate concentration response curve following direct 
stimulation was obtained which revealed an EC50 = 1ߤM. Furthermore, increasing glutamate 
concentrations resulted in concomitant increases in neuronal activation in adjacent networks. 
Pharmacological manipulation of neuronal activity was also achieved as the neuronal response to 
glutamate was reversibly reduced in the presence of ionotropic glutamatergic antagonists. 
Conclusion: The proposed microfluidic system is able to reliably produce pharmacological profiles for 
drugs in a neurological setting. The ability to not only determine the properties of a new drug, but 
how the drug influences communication between neural networks makes this model a novel drug 
discovery platform. 
